Neuropathix, Inc.
NPTX · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $183,477,000 | $0 | $126 | $174 |
| % Growth | – | -100% | -27.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $183,477,000 | $0 | $126 | $174 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $452 | $1,095 | $555 | $225 |
| G&A Expenses | $2,672 | $3,378 | $1,900 | $1,011 |
| SG&A Expenses | $2,672 | $3,378 | $1,900 | $1,011 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$183 | $0 | $0 | $0 |
| Operating Expenses | $2,941 | $4,474 | $2,455 | $1,236 |
| Operating Income | -$2,941 | -$4,474 | -$2,329 | -$1,062 |
| % Margin | -0% | – | -1,848.1% | -610.6% |
| Other Income/Exp. Net | $2,940,632,442 | -$64 | -$1,122 | $2,805 |
| Pre-Tax Income | -$3,558 | -$4,537 | -$3,451 | $1,743 |
| Tax Expense | $435 | $1,032 | $1,115 | $812 |
| Net Income | -$3,992 | -$5,570 | -$4,566 | $937 |
| % Margin | -0% | – | -3,622.9% | 538.7% |
| EPS | -0.046 | -0.075 | -0.064 | 0.014 |
| % Growth | 38.9% | -16.4% | -571.3% | – |
| EPS Diluted | -0.046 | -0.075 | -0.064 | 0.014 |
| Weighted Avg Shares Out | 87,576 | 74,624 | 71,228 | 68,849 |
| Weighted Avg Shares Out Dil | 87,576 | 74,624 | 71,228 | 68,849 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $435 | $924 | $0 | $0 |
| Depreciation & Amortization | $21 | $124 | $980 | $2,811 |
| EBITDA | -$2,920 | -$4,349 | -$1,349 | $41 |
| % Margin | -0% | – | -1,070.2% | 23.4% |